POLG Mutations Are Probably Rare in the Han Chinese Population

Area of Science:

• Genetics
• Neurology
• Pharmacogenomics

Background:

• Mutations in the polymerase gamma gene (POLG) are implicated in early-onset, intractable epilepsy.
• Understanding POLG variant prevalence is crucial for diagnosing and managing epilepsy, particularly in diverse ethnic groups.
• Valproic acid (VPA) is a common antiepileptic drug, and its safety profile can be influenced by genetic factors.

Purpose of the Study:

• To determine the incidence and prevalence of pathogenic POLG variants in Han Chinese epilepsy patients.
• To assess the safety of valproic acid (VPA) treatment in this cohort, specifically regarding hepatic toxicity.
• To investigate the potential role of POLG mutations in non-syndromic intractable epilepsy within the Han Chinese population.

Main Methods:

• DNA sequencing of the POLG gene was performed on 216 Han Chinese pediatric epilepsy patients.
• Patients were selected based on seizure diagnosis prior to valproic acid (VPA) exposure.
• Clinical data, including onset age, epilepsy course, and liver function tests post-VPA treatment, were collected.

Main Results:

• No homozygous or compound heterozygous pathogenic POLG mutations were detected in the study cohort.
• Three patients exhibited single heterozygous POLG variants (c.1150G>T, p.D384Y, c.156_158dupGCA), none of which were deemed clinically significant.
• None of the patients experienced hepatic toxicity following standard-dose VPA treatment.

Conclusions:

• Functional POLG homozygous and compound heterozygous mutations appear to be rare in the studied Han Chinese epilepsy patient population.
• Standard therapeutic dosages of valproic acid (VPA) seem to be safe concerning hepatic toxicity in this cohort.
• The findings suggest that POLG mutations may not be a primary genetic cause of intractable epilepsy in Han Chinese individuals.